Wave Life Sciences Ltd. (WVE)
Wave Life Sciences shares plummet on weight loss therapy update
Wave Life Sciences (NASDAQ:WVE) saw its shares fall more than 52% following the release of six-month Phase 1 data for WVE-007, its investigational INHBE GalNAc-siRNA therapy, despite results showing improvements in body composition and continued safety and tolerability. The Phase 1 INLIGHT trial reported that a single 240 mg dose of WVE-007 produced placebo-adjusted reductions of 14.3% in visceral fat, 5% in total fat, a 2% increase in lean mass, a 3.3% reduction in waist circumference, and a 0.9% reduction in body weight after six months.
WAVE Life Sciences Ltd. (NASDAQ:WVE) Given Consensus Rating of “Moderate Buy” by Brokerages
Shares of WAVE Life Sciences Ltd. (NASDAQ: WVE - Get Free Report) have received an average rating of "Moderate Buy" from the fourteen brokerages that are covering the stock, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell rating and thirteen have given a buy rating to the company. The average 12-month
Wave Life Sciences Ltd. (WVE) Q4 2025 Earnings Call Transcript
Wave Life Sciences Ltd. (WVE) Q4 2025 Earnings Call Transcript
Wave Life Sciences Ltd. (WVE) Presents at 44th Annual J.P.
Wave Life Sciences Ltd. (WVE) Presents at 44th Annual J.P.
Why Did Wave Life Sciences Surge 147%?
A surge of 147% in a single session is an unusual occurrence in biotech — and nearly unprecedented for a company that has spent years trading discreetly under the radar. However, that is precisely what transpired with Wave Life Sciences (NASDAQ:WVE), the RNA-focused drug developer that astonished Wall Street with data so unexpectedly robust that it reshaped the company's future in just a few hours.
WVE Stock Surges More Than 180% in a Week: What Is Driving This Rally?
Wave Life Sciences' shares jump 183% as early INLIGHT data on weight-loss drug WVE-007 show notable visceral fat cuts and gains in lean mass.
Wave Life Sciences Ltd. (WVE) Discusses Positive Interim Data from INLIGHT Trial of WVE-007 for Obesity Transcript
Wave Life Sciences Ltd. (WVE) Discusses Positive Interim Data from INLIGHT Trial of WVE-007 for Obesity Transcript
Wave Life Sciences surges after early data shows fat loss benefits from experimental obesity drug
Shares of Wave Life Sciences (NASDAQ:WVE) surged more than 126% on Monday after the biotech company reported early clinical data showing its experimental obesity treatment led to significant reductions in body fat and gains in lean mass. The Phase 1 study gave participants a single 240 mg injection of WVE-007, an experimental therapy.
Wave Life Sciences: Being Realistic, There Is Still So Much To Prove
Wave Life Sciences Ltd. remains a high-risk, high-reward biotech with a unique RNA-based pipeline targeting AATD, obesity, DMD, and Huntington's Disease. I maintain a speculative Buy rating, driven by differentiated AATD and obesity assets, despite limited clinical proof and substantial cash burn. WVE's near-term catalysts include 2026 clinical readouts for AATD and obesity programs, with potential for significant upside if data are positive.
Wave Life Sciences Ltd. (WVE) Q3 2025 Earnings Call Transcript
Wave Life Sciences Ltd. ( WVE ) Q3 2025 Earnings Call November 10, 2025 8:30 AM EST Company Participants Kate Rausch - Head of Investor Relations Paul Bolno - President, CEO & Director Kyle Moran - CFO & Principal Accounting Officer Erik Ingelsson - Chief Scientific Officer Christopher Wright - Chief Medical Officer Chandra Vargeese - Chief Technology Officer Conference Call Participants Joon Lee - Truist Securities, Inc., Research Division Cheng Li - Oppenheimer & Co. Inc., Research Division Salim Syed Steven Seedhouse - Cantor Fitzgerald & Co., Research Division Madison Wynne El-Saadi - B.
Wave Life Sciences (WVE) Reports Q3 Loss, Misses Revenue Estimates
Wave Life Sciences (WVE) came out with a quarterly loss of $0.32 per share versus the Zacks Consensus Estimate of a loss of $0.3. This compares to a loss of $0.47 per share a year ago.
Wave Life Sciences Ltd. (WVE) Spotlight on RNA Editing and RNAi: Pipeline and Clinical Advances in Oligonucleotide Therapeutics Transcript
Wave Life Sciences Ltd. ( WVE ) Spotlight on RNA Editing and RNAi: Pipeline and Clinical Advances in Oligonucleotide Therapeutics October 29, 2025 10:00 AM EDT Company Participants Kate Rausch - Head of Investor Relations Paul Bolno - President, CEO & Director Christopher Wright - Chief Medical Officer Erik Ingelsson - Chief Scientific Officer Chandra Vargeese - Chief Technology Officer Conference Call Participants Joon Lee - Truist Securities, Inc., Research Division Joseph Schwartz - Leerink Partners LLC, Research Division Steven Seedhouse - Cantor Fitzgerald & Co., Research Division Yun Zhong - Wedbush Securities Inc., Research Division Salim Syed - Mizuho Securities USA LLC, Research Division Cheng Li - Oppenheimer & Co. Inc., Research Division Cha Cha Yang - Jefferies LLC, Research Division Catherine Novack - JonesTrading Institutional Services, LLC, Research Division William Maughan Madison Wynne El-Saadi - B.
